| Identification | Back Directory | [Name]
2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one | [CAS]
851398-76-0 | [Synonyms]
N6F11
2-(chloromethyl)-6-(4-chlorophenyl)-3H,4H-thieno[3,2-d]pyrimidin-4-one
Thieno[3,2-d]pyrimidin-4(3H)-one, 2-(chloromethyl)-6-(4-chlorophenyl)- | [Molecular Formula]
C13H8Cl2N2OS | [MDL Number]
MFCD06380389 | [MOL File]
851398-76-0.mol | [Molecular Weight]
311.19 |
| Hazard Information | Back Directory | [Uses]
N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+ T cells[1][2][3][4]. | [References]
[1] Li J, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049. DOI:10.1126/scitranslmed.adg3049
[2] Liu J, et al. Cell type-specific induction of ferroptosis to boost antitumor immunity. Oncoimmunology. 2023 Nov 20;12(1):2282252. DOI:10.1080/2162402X.2023.2282252
[3] Shi TM, et al. Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer. J Med Chem. 2024 Feb 22;67(4):2238-2263. DOI:10.1021/acs.jmedchem.3c01749
[4] Liu J, et al. Adverse effects of ferroptotic therapy: mechanisms and management. Trends Cancer. 2024 May;10(5):417-429. DOI:10.1016/j.trecan.2024.01.002 |
|
|